Evidence map›Paper›PMID 33310368›Full record

ArticleCancer treatment and research communications2020

Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience.

Wanyuan Cui, Nadia Yousaf, Jaishree Bhosle, Anna Minchom, Andrew G Nicholson, Merina Ahmed, Fiona McDonald, Imogen Locke, Richard Lee, Mary O'Brien and 1 more

Abstract read
In one paragraph

Article in Cancer treatment and research communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wanyuan CuiLung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Nadia YousafLung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Jaishree BhosleLung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Anna MinchomLung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Andrew G NicholsonNational Heart and Lung Institute, Imperial College London, London, United Kingdom; Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Merina AhmedLung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Fiona McDonaldLung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Imogen LockeLung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Richard LeeLung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom; National Heart and Lung Institute, Imperial College London, London, United Kingdom; ICR NIHR Biomedical Research Centre.
Mary O'BrienLung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Sanjay PopatLung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom; National Heart and Lung Institute, Imperial College London, London, United Kingdom; Thoracic Oncology, Institute of Cancer Research, London, United Kingdom. Electronic address: sanjay.popat@rmh.nhs.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUK COVID-19 mortality rates are amongst the highest globally. Controversy exists on the vulnerability of thoracic cancer patients. We describe the characteristics and sequelae of patients with thoracic cancer treated at a UK cancer centre infected with COVID-19.

methodsPatients undergoing care for thoracic cancer diagnosed with COVID-19 (RT-PCR/radiology/clinically) between March-June 2020 were included. Data were extracted from patient records.

resultsThirty-two patients were included: 14 (43%) diagnosed by RT-PCR, 18 (57%) by radiology and/or convincing symptoms. 88% had advanced thoracic malignancies. Eleven of 14 (79%) patients diagnosed by RT-PCR and 12 of 18 (56%) patients diagnosed by radiology/clinically were hospitalised, of which four (29%) and 2 (11%) patients required high-dependency/intensive care respectively. Three (21%) patients diagnosed by RT-PCR and 2 (11%) patients diagnosed by radiology/clinically required non-invasive ventilation; none were intubated. Complications included pneumonia and sepsis (43% and 14% respectively in patients diagnosed by RT-PCR; 17% and 11% respectively in patients diagnosed by radiology/clinically). In patients receiving active cancer treatment, therapy was delayed/ceased in 10/12 (83%) and 7/11 (64%) patients diagnosed by RT-PCR and radiology/clinically respectively. Nine (28%) patients died; all were smokers. Median time from symptom onset to death was 7 days (range 3-37).

conclusionsThe immediate morbidity from COVID-19 is high in thoracic cancer patients. Hospitalisation and treatment interruption rates were high. Improved risk-stratification models for UK cancer patients are urgently needed to guide safe cancer-care delivery without compromising efficacy.

Indexed as

AdultCOVID-19Critical CareFemaleHospitalizationHumansMaleMiddle AgedSARS-CoV-2Thoracic NeoplasmsUnited KingdomCovid-19;LUng cancerThoracic cancer

Identifiers

PMID33310368
PMCPMC7709731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.